Showing results (1661-1670 of 6,511) with videos related to
Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|June 9, 2019
Pembrolizumab as first-line treatment for metastatic uveal melanomaErnesto Rossi, Monica Maria Pagliara, Daniela Orteschi, et al.Cancer Immunology, Immunotherapy : CII|August 1, 1997
Interleukin-1alpha synergistic in vivo enhancement of cyclophosphamide- and carboplatin-mediated antitumor activityW D Yu, M J Chang, D L Trump, et al.Cancer Immunology, Immunotherapy : CII|August 1, 1997
Variable expression of tumor necrosis factor alpha in human malignant melanoma localized by in situ hybridization for mRNAC Bergenwald, G Westermark, B SanderCancer Immunology, Immunotherapy : CII|August 7, 2016
Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpGHila Confino, Michael Schmidt, Margalit Efrati, et al.Cancer Immunology, Immunotherapy : CII|July 28, 2016
Concepts in glioma immunotherapyMichael Platten, Lukas Bunse, Wolfgang Wick, et al.Cancer Immunology, Immunotherapy : CII|July 25, 2016
Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysisHidenori Takahashi, Shigetaka Shimodaira, Masahiro Ogasawara, et al.Cancer Immunology, Immunotherapy : CII|January 24, 1998
Early-appearing tumor-infiltrating natural killer cells play an important role in the nitric oxide production of tumor-associated macrophages through their interferon productionK Abe, M Harada, K Tamada, et al.Cancer Immunology, Immunotherapy : CII|January 24, 1998
The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and backA M Berghella, P Pellegrini, T Del Beato, et al.Cancer Immunology, Immunotherapy : CII|January 22, 1998
Tumor-specific T-bodies: towards clinical applicationZ EshharCancer Immunology, Immunotherapy : CII|January 22, 1998
Fc gamma RI blockade and modulation for immunotherapyP K Wallace, T Keler, P M Guyre, et al.Pageof 652